Arkolith/Insider Trading/AGIO/Form 4

Ho Maykin

DirectorAGIOS PHARMACEUTICALS, INC. (AGIO) · full profile →Form 4 · filed Jun 23, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
1 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 18, 2026Option exercise(M)3K—$020K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 18, 2026Option exercise(M)3K—$00
Jun 18, 2026Grant(A)3K—$03K
Jun 18, 2026Grant(A)15K—$015K

Transaction Codes

M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001439222-26-000099) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML